{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:10:10Z","timestamp":1758899410161,"version":"3.44.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13300-025-01782-z","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T07:55:10Z","timestamp":1755590110000},"page":"2063-2070","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sacubitril\/Valsartan-Induced Hypoglycemia After Gastric Bypass: A Case Report with Documented Endogenous Hyperinsulinemia"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1657-8642","authenticated-orcid":false,"given":"Mona","family":"Guetlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Morera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"1782_CR1","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2019-0185","author":"LO Lazar","year":"2019","unstructured":"Lazar LO, Sapojnikov S, Pines G, Mavor E, Ostrovsky V, Schiller T, et al. Symptomatic and asymptomatic hypoglycemia post three different bariatric procedures: a common and severe complication. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2019. https:\/\/doi.org\/10.4158\/EP-2019-0185","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"issue":"3","key":"1782_CR2","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1016\/j.soard.2014.11.003","volume":"11","author":"R Kefurt","year":"2015","unstructured":"Kefurt R, Langer FB, Schindler K, Shakeri-Leidenm\u00fchler S, Ludvik B, Prager G. Hypoglycemia after Roux-En-Y gastric bypass: detection rates of continuous glucose monitoring (continuous glucose monitoring (CGM)) versus mixed meal test. Surg Obes Relat Dis. 2015;11(3):5649.","journal-title":"Surg Obes Relat Dis."},{"issue":"8","key":"1782_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41574-020-0357-5","volume":"16","author":"E Scarpellini","year":"2020","unstructured":"Scarpellini E, Arts J, Karamanolis G, et al. International consensus on the diagnosis and management of dumping syndrome. Nat Rev Endocrinol. 2020;16(8):448\u201366.","journal-title":"Nat Rev Endocrinol"},{"key":"1782_CR4","volume":"13","author":"A Sheehan","year":"2020","unstructured":"Sheehan A, Patti ME. Hypoglycemia after upper gastrointestinal surgery: clinical approach to assessment, diagnosis, and treatment. Diabetes Metab Syndr Obes Targets Ther. 2020;13: 446982.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"5","key":"1782_CR5","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1016\/j.soard.2011.08.008","volume":"8","author":"EP Ceppa","year":"2012","unstructured":"Ceppa EP, Ceppa DP, Omotosho PA, Dickerson JA, Park CW, Portenier DD. Algorithm to diagnose etiology of hypoglycaemia after Roux-en-Y gastric bypass for morbid obesity: case series and review of the literature. Surg Obes Relat Dis. 2012;8(5):6417.","journal-title":"Surg Obes Relat Dis."},{"key":"1782_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30087-6","author":"JP Seferovic","year":"2017","unstructured":"Seferovic JP, et al. Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017. https:\/\/doi.org\/10.1016\/S2213-8587(17)30087-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"17","key":"1782_CR7","doi-asserted-by":"publisher","first-page":"160920","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):160920.","journal-title":"N Engl J Med"},{"issue":"1","key":"1782_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12933-022-01545-1","volume":"21","author":"MO Wijkman","year":"2022","unstructured":"Wijkman MO, Claggett B, Vaduganathan M, Cunningham JW, R\u00f8rth R, Jackson A, et al. Effects of sacubitril\/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022;21(1):110.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"1782_CR9","doi-asserted-by":"publisher","first-page":"12545","DOI":"10.1177\/1932296818785644","volume":"12","author":"E Gamarra","year":"2018","unstructured":"Gamarra E, Baffoni C, Borretta G, Feola M, Tassone F. Reduction of insulin requirement after starting treatment with sacubitril\/valsartan in a patient with diabetes treated with continuous subcutaneous insulin infusion (CSII): a case report. J Diabetes Sci Technol. 2018;12(6):12545.","journal-title":"J Diabetes Sci Technol"},{"issue":"3","key":"1782_CR10","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.cjco.2020.02.002","volume":"2","author":"AR Barry","year":"2020","unstructured":"Barry AR. Severe hypoglycemia in a patient with type 1 diabetes mellitus recently started on sacubitril\/valsartan: a case report. CJC Open. 2020;2(3):1768.","journal-title":"CJC Open"},{"issue":"5","key":"1782_CR11","first-page":"3969","volume":"5","author":"G Morgan","year":"2022","unstructured":"Morgan G, Chowdhury SR. Resolution of hypoglycemia following cessation of sacubitril-valsartan combination therapy in a nondiabetic patient. CJC Open. 2022;5(5):3969.","journal-title":"CJC Open."},{"key":"1782_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.888867","author":"N Esser","year":"2022","unstructured":"Esser N, Schmidt C, Barrow BM, Cronic L, Hackney DJ, Mongovin SM, et al. Insulinotropic effects of neprilysin and\/or angiotensin receptor inhibition in mice. Front Endocrinol. 2022. https:\/\/doi.org\/10.3389\/fendo.2022.888867.","journal-title":"Front Endocrinol"},{"issue":"5","key":"1782_CR13","doi-asserted-by":"publisher","first-page":"17580","DOI":"10.1080\/19382014.2018.1502521","volume":"10","author":"N Esser","year":"2018","unstructured":"Esser N, Barrow BM, Choung E, Shen NJ, Zraika S. Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor-dependent manner. Islets. 2018;10(5):17580.","journal-title":"Islets"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01782-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01782-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01782-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T14:40:54Z","timestamp":1758897654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01782-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1782"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01782-z","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"type":"print","value":"1869-6953"},{"type":"electronic","value":"1869-6961"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest, financial or non-financial, related to the content of this article. Michael Joubert is an Editorial Board member of Diabetes Therapy. Michael Joubert was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This case report did not require ethical approval. Written informed consent was obtained from the patient for participation and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}